Market Overview

FBR Capital Initiates TherapeuticsMD At Outperform, Shares Jump

Watch These 5 Huge Put Purchases In Wednesday Trade
Benzinga's Top Initiations
Avoid These Biotech Stocks - Cramer's Lightning Round (12/1/16) (Seeking Alpha)

FBR Capital Markets initiated coverage on shares of TherapeuticsMD (NYSE: TXMD) with an “outperform” rating.

The target price for TherapeuticsMD is set to $34.

TherapeuticsMD shares have jumped 54.10% over the past 52 weeks, while the S&P 500 index has gained 19.69% in the same period.

TherapeuticsMD's shares jumped 32.93% to $5.49 in pre-market trading.

Latest Ratings for TXMD

Nov 2016OppenheimerInitiates Coverage OnOutperform
Nov 2016GuggenheimAssumesBuy
Apr 2016Goldman SachsInitiates Coverage onBuy

View More Analyst Ratings for TXMD
View the Latest Analyst Ratings

Posted-In: FBR Capital MarketsInitiation Analyst Ratings


Related Articles (TXMD)

View Comments and Join the Discussion!